Moderna 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   2 Trials   3 News 
193 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
intismeran autogene (mRNA-4157) / Merck (MSD), Moderna
INTerpath-009, NCT06623422: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/)

Recruiting
3
680
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, Platinol®, Platinol®-AQ, Carboplatin, Paraplatin®, Pemetrexed, Alimta®, Gemcitabine, Gemzar, Paclitaxel, Taxol®, Onxol®, Intismeran autogene, mRNA-4157, V940, Placebo
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Carcinoma, Non-Small-Cell Lung
05/33
01/38
INTerpath-001, NCT05933577: A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Active, not recruiting
3
1089
Europe, Canada, Japan, US, RoW
Intismeran autogene, mRNA-4157, Individualized neoantigen therapy, V940, Pembrolizumab, MK-3475, Keytruda®, Placebo, Normal saline, Dextrose
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Melanoma
10/29
09/30
INTerpath-002, NCT06077760: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Recruiting
3
868
Europe, Canada, Japan, US, RoW
Intismeran autogene, mRNA-4157, V940, Pembrolizumab, MK-3475, KEYTRUDA®, Placebo
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Non-small Cell Lung Cancer
06/30
12/35
INTerpath-007, NCT06295809: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007).

Active, not recruiting
2/3
1012
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Intismeran autogene, mRNA-4157, V940, Surgery
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Carcinoma, Squamous Cell, Skin Neoplasms
03/26
03/26
INTerpath-004, NCT06307431: A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Active, not recruiting
2
272
Europe, Canada, US, RoW
Intismeran autogene, mRNA-4157, V940, Pembrolizumab, MK-3475, KEYTRUDA®, Placebo
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Renal Cell Carcinoma
01/28
06/32
INTerpath-011, NCT06833073: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/)

Recruiting
2
308
US, RoW
Intismeran autogene, mRNA-4157, V940, BCG, BCG Live, TICE®, TheraCys®
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
09/31
09/31
INTerpath-012, NCT06961006: A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/)

Not yet recruiting
2
160
NA
V940, mRNA-4157, Pembrolizumab, MK-3475, KEYTRUDA®, Placebo
Merck Sharp & Dohme LLC
Malignant Melanoma
07/28
09/31
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
INTerpath-005, NCT06305767: A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/)

Recruiting
1/2
230
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Intismeran autogene, V940, Placebo, Enfortumab Vedotin, PADCEV®, Surgery (RC plus PLND)
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Bladder Cancer
04/27
10/31
KEYNOTE-603, NCT03313778: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Recruiting
1
242
Europe, Japan, US, RoW
mRNA-4157, Pembrolizumab, SoC Treatment, Standard of care chemotherapy
ModernaTX, Inc., Merck Sharp & Dohme LLC
Solid Tumors
06/25
06/25
VX-522 / Vertex, Moderna
VX21-522-001, NCT05668741: A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Recruiting
1/2
33
Europe, Canada, US, RoW
VX-522 mRNA therapy, IVA, ivacaftor, VX-770
Vertex Pharmaceuticals Incorporated, Moderna, Inc
Cystic Fibrosis
03/25
03/25
mRNA-2752 / Moderna
NCT02872025: Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

Active, not recruiting
1
42
US
Pembrolizumab, Keytruda, MK-3475, Intralesional mRNA 2752, mRNA 2752
Laura Esserman, Merck Sharp & Dohme LLC, ModernaTX, Inc.
Carcinoma, Intraductal, Noninfiltrating
03/26
03/26
mRNA-2752-P101, NCT03739931: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Checkmark Data in combination with mRNA-2752 in solid tumors and lymphomas at SITC 2021
Nov 2021 - Nov 2021: Data in combination with mRNA-2752 in solid tumors and lymphomas at SITC 2021
Active, not recruiting
1
134
US, RoW
mRNA-2752, Durvalumab
ModernaTX, Inc., AstraZeneca
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
12/25
12/25
MEDI1191 / Moderna
D8510C00001, NCT03946800: A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Completed
1
61
Europe, US
MEDI1191, Durvalumab
MedImmune LLC
Solid Tumors, Cancer
08/23
08/23
mRNA-1644 / Moderna
NCT05001373: A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Active, not recruiting
1
56
US
Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
International AIDS Vaccine Initiative, ModernaTX, Inc., George Washington University, Fred Hutchinson Cancer Center, Emory University, UT Health San Antonio
Hiv
06/23
07/24
NCT05414786: A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

Active, not recruiting
1
18
RoW
eOD-GT8 60mer mRNA Vaccine (100µg)
International AIDS Vaccine Initiative, AURUM Tembisa Clinical Research, Center for Family Health Research, ModernaTX, Inc.
HIV-1-infection
06/23
06/23
mRNA-3927 / Moderna
2019-003529-36: A clinical study to evaluate the medicinal product in Patients with Propionic Acidemia

Not yet recruiting
1/2
36
Europe
mRNA-3927, Injection
ModernaTX, Inc, ModernaTX, Inc.
Propionic Acidemia- Propionic acidemia is an autosomal recessive disorder caused by loss-of-function mutations in PCCA or PCCB (and in rare instances, mutations in both PCCA and PCCB), resulting in the loss of enzymatic activity of the mitochondrial complex PCC, Deficiency of PCCA and PCCB, Body processes [G] - Metabolic Phenomena [G03]
 
 
mRNA-3927-P101, NCT04159103 / 2019-003529-36: Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Recruiting
1/2
68
Europe, Canada, Japan, US
mRNA-3927
ModernaTX, Inc., ModernaTX, Inc.
Propionic Acidemia
01/26
01/26
NCT05130437: A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Recruiting
1/2
36
Europe, Canada, US
mRNA-3927
ModernaTX, Inc.
Propionic Acidemia
12/29
12/31
mRNA-1647 / Moderna
NCT05085366 / 2020-006051-17: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Active, not recruiting
3
7454
Europe, Canada, Japan, US, RoW
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
04/26
04/28
NCT06133010: A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Withdrawn
2
342
NA
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
02/27
12/27
NCT05683457: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Recruiting
2
224
US
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
08/26
08/26
NCT04975893: A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Enrolling by invitation
2
291
US
mRNA-1647
ModernaTX, Inc.
Cytomegalovirus Infection
12/26
12/26
2022-001545-20: A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Not yet recruiting
1/2
770
Canada, Europe, US
mRNA-1647, mRNA-1647, Injection
ModernaTX, Inc., ModernaTX, Inc.
Cytomegalovirus infection, Cytomegalovirus infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT05575492 / 2022-001545-20: A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Recruiting
1/2
770
Europe, Canada, US
mRNA-1647, Placebo
ModernaTX, Inc., ModernaTX, Inc.
Cytomegalovirus
01/27
01/27
NCT05105048: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

Completed
1
9
US
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
08/23
08/23
NCT05397223: A Study of Modified mRNA Vaccines in Healthy Adults

Active, not recruiting
1
308
US
mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
ModernaTX, Inc.
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
02/26
02/26
Spikevax (elasomeran) / Moderna
2021-004788-29: COVID-19 vaccine immunology Koronarokoteimmunologia

Ongoing
4
4000
Europe
Concentrate for dispersion for injection, Dispersion for injection, Suspension for injection, , Comirnaty, Spikevax, Vaxzevria, Tutkimuksen kohteena ovat Suomen kansallisen koronarokoteohjelman tarjoamat COVID-19 rokotteet. Tämä koskee myös tutkimuksen aikana tällaiseen käyttöön tulevia COVID-19 rokotteita, mukaan lukien yhdistelmärokotteet.
Finnish Institute for Health and Welfare, Finnish Institute for Health and Welfare
Tutkittavat ovat terveitä (Immuniteetti COVID-19 infektiota vastaan), Tutkittavat ovat terveitä (Immuniteetti COVID-19 infektiota vastaan), Body processes [G] - Immune system processes [G12]
 
 
ACTRN12622000238774: A randomised trial to evaluate the immune response of COVID-19 vaccines in adults and adolescents

Recruiting
4
1325
 
The Kids Research Institute Australia, National Health and Medical Research Council (NHMRC), Snow Medical Research Foundation
COVID-19
 
 
2021-001054-57: SARS-CoV-2 vaccination study in people living with HIV SARS-CoV-2 vaccinatie studie in mensen die leven met HIV

Ongoing
4
1650
Europe
COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine (ChAdOx1-S [recombinant]), EMEA/H/C/005791, EMEA/H/C/005735, EMEA/H/C/005675, Dispersion for injection, Concentrate for dispersion for infusion, Suspension for injection, COVID-19 Vaccine Moderna, Comirnaty, COVID-19 Vaccine AstraZeneca
OLVG, ZonMW
COVID-19 vaccine response in people living with HIV COVID-19 vaccinatie respons in mensen die leven met HIV, COVID-19 vaccination effect in people living with HIV COVID-19 vaccinatie effect in mensen die leven met HIV, Diseases [C] - Virus Diseases [C02]
 
 
2021-000206-17: Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. Studier av pågående och genomgången SARS-CoV-2 infektion (som orsakar COVID-19) inom vård och omsorg i Stockholms län, med avseende på vaccinationer.

Ongoing
4
10000
Europe
Concentrate for solution for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Karolinska University Hospital, Karolinska University Hospital
Vaccination against COVID-19. Vaccination mot COVID-19., Vaccination against COVID-19. Vaccination mot COVID-19., Diseases [C] - Virus Diseases [C02]
 
 
2021-000710-42: Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC study) Onderzoek naar het effect van de COVID-vaccinatie bij patiënten die behandeld worden met rituximab (de RTX-COVAC studie).

Ongoing
4
270
Europe
COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, Concentrate for solution for injection, Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Sint Maartenskliniek, Sint Maartenskliniek
Rheumatoid arthritis Reumatoïde artritis, Rheumatic disease Reuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2021-000440-22: Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium

Ongoing
4
420
Europe
Comirnaty, Covid19 Vaccine Moderna, Covid 19 Vaccine AstraZeneca, J07BX03, Injection, Comirnaty, Covid-19 Vaccine Moderna, COVID19 Vaccine Astrazeneca
Universiteit Antwerpen, Sciensano
Vaccine responses to COVID19 vaccines administered in pregnant andlactating women, Corona virus vaccine responses in pregnant and lactating women, Diseases [C] - Virus Diseases [C02]
 
 
2021-000349-42: Evaluation of How Long Immune Responses to SARS-CoV-2 Persist Following COVID-19 Vaccination

Ongoing
4
500
Europe
Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Sahlgrenska Academy, University of Gothenburg
COVID-19, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-000905-26: Response to Covid-19 vaccination in patients with cancer

Ongoing
4
150
Europe
Concentrate for dispersion for infusion, Concentrate for solution for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Department of Oncology, Uppsala University Hospita, Department of Oncology, Uppsala University Hospital
Immune response to Covid-19 vaccination of patients with immune modulatory treatment for cancer, Response to Covid-19 vaccination in patients with treatment for cancer, Body processes [G] - Immune system processes [G12]
 
 
2021-001769-19: Immune response to SARS-CoV-2 in health care workers, previously infected subjects, and immunocompromised subjects, before and after Covid-19 vaccination: a phase IV trial

Ongoing
4
1200
Europe
Injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, COVID-19 Vaccine Janssen
GUVAX (Gothenburg University Vaccine Research Institute), SciLife
SARS-COV-2 infection, Coronavirus disease, Diseases [C] - Virus Diseases [C02]
 
 
2021-002014-14: Monitoring of antibody response 28 days after the first dose of COVID19 vaccine in clinically stable subjects with functional kidney transplantation. Sledování protilátkové odpovědi v intervalu 28 dní po první dávce vakcíny proti COVID19 u klinicky stabilních osob s funkční transplantovanou ledvinou.

Ongoing
4
60
RoW
Fakultní nemocnice Hradec Králové, Hemodialyzační středisko Fakultní nemocnice Hradec Králové
Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) in clinically stable patients with functional kidney transplantation. Protilátková a buněčná odpověď v odstupu 28 dní po podání první dávky COVID-19 vakcíny (Moderna) u klinicky stabilních pacientů s funkční transplantovanou ledvinou., Monitoring of antibody response 28 days after the first dose of COVID19 vaccine in clinically stable subjects with functional kidney transplantation. Sledování protilátkové odpovědi v intervalu 28 dní po první dávce vakcíny proti COVID19 u klinicky stabilních osob s funkční transplantovanou ledvinou., Body processes [G] - Immune system processes [G12]
 
 
2021-001993-52: Immunogenicity after COVID-19 vaccines in adapted schedules

Not yet recruiting
4
560
Europe
Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, Vaxzevria
University of Antwerp, Belgian Health Care Knowledge Centre (KCE)
Coronavirus disease-19 (COVID-19), COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-001976-40: SARS-Cov-2 vaccine responsiveness in middle-aged and older persons

Not yet recruiting
4
1700
Europe
Suspension for injection, Comirnaty, Spikevax, Vaxzevria, COVID-19 Vaccine Janssen
National Institute for Public Health and the Environment, National Institute for Public Health and the Environment
SARS-CoV-19, frailty, COVID-19, frailty, Body processes [G] - Immune system processes [G12]
 
 
IMCOVAS, NCT06189040: Immunogenicity After COVID-19 Vaccines in Adapted Schedules

Completed
4
580
Europe
BNT162b2 30µg, BNT162b2 20µg, BNT162b2 6µg, mRNA-1273 100µg, mRNA-1273 50µg, ChAdOx1-S [Recombinant]
Universiteit Antwerpen
Coronavirus Disease 2019, COVID-19
11/21
07/22
2021-002363-22: Vaccination of older persons against SARS-CoV2 and inducing cellular immunity

Not yet recruiting
4
150
Europe
Suspension for injection, Comirnaty, Spikevax, Vaxzevria, COVID-19 Vaccine Janssen
National Institute for Public Health and the Environment, National Institute for Public Health and the Environment
SARS-CoV-19, frailty, COVID-19, frailty, Body processes [G] - Immune system processes [G12]
 
 
2021-002613-34: Effectivity of COVID-19 vaccination in people with Down syndrome

Ongoing
4
640
Europe
Concentrate for dispersion for injection, Dispersion for injection, Suspension for injection, Comirnaty COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine Moderna, Vaxzevria
University Medical Center Utrecht, ZonMw
Persons with Down syndrome, Persons with Down syndrome, Body processes [G] - Immune system processes [G12]
 
 
2021-003618-37: Booster dose of SARS-CoV-2 vaccine to patients with suboptimal response to previous doses.

Ongoing
4
1000
Europe
SARS-CoV-2 mRNA, Concentrate for dispersion for injection, Concentrate and solvent for solution for injection, Comirnaty, Spikevax
Oslo University Hospital, Oslo University Hospital
Patients with immune deficiency without proper response to previous SARS-CoV-2 vaccine doses., Vaccination for protection against COVID-19, Diseases [C] - Immune System Diseases [C20]
 
 
2021-003386-35: Vaccination for Recovered Inpatients with COVID-19 (VATICO) Vacunación para pacientes hospitalizados recuperados con COVID-19 (VATICO)

Ongoing
4
640
Europe
Concentrate for solution for injection, COMIRNATY concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), Spikevax dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)
Regents of the University of Minesota, National Insitute of Health
Participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still [TICO assignment] blinded, and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups of the Moderna mRNA 1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines) Los participantes del ens. clín. ACTIV-3/TICO en los centros seleccionados que recibieron agentes en investigación ciegos o placebo preespecificados como parte de ese ensayo, y que han logrado una recuperación sostenida, y que todavía están [asignación de TICO] cegados, y que todavía están dentro de los 28 a 90 días después de la aleatoriz. inicial de TICO, serán aleatorizados en este diseño factorial 2x2 a uno de los cuatro grupos de la vacuna Moderna mRNA 1273 o Pfizer BNT162b2 (vac. de ARNm), Same as above Igual que arriba, Health Care [N] - Environment and Public Health [N06]
 
 
ACTRN12622001106729: Safety and efficacy of the 3rd and the 4th dose of mRNA COVID19 vaccine in kidney transplant recipients

Completed
4
140
 
Martin Kacer, Fighting INfectious Diseases "FIND"; Ministry of Education, Youth and Sports of the Czech Republic, Cooperatio; Charles University in Prague
COVID19 vaccination response, Kidney transplant recipients
 
 
2021-004558-44: Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients Optimale booster strategie voor SARS-CoV-2 vaccinatie in niertransplantatie patiënten.

Ongoing
4
460
Europe
Solution for injection, Spikevax, COVID-19 Vaccine Janssen
UMCG, ZonMW
COVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate mofetil (MMF) / mycophenolic acid (MPA). COVID-19 is geassocieerd met ernstig vergroot risico op ziekte en mortaliteit in niertransplantatie patiënten. Beschikbare data laat zien dat de immuunrespons na een standaard programma van 2 mRNA vaccinaties ernstig lager is in niertransplantatie patienten dan in een controle groep, zeker wanneer hun immuunsuppressie therapie MMF/MPA bevat., Many kidneytransplant patients are none responsive to the current Covid-19 vaccination regime. Therefore it is important to know whether a booster vaccine will increase the efficacy of vaccination. Veel niertransplantatie patienten hebben geen respons op het huidige Covid-19 vaccinatie beleid. Het is daarom van belang om te weten of een booster vaccin de effectiviteit van vaccinatie vergroot., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-004608-17: Effectivity of a mRNA-1273 booster vaccine against Covid-19 breakthrough infections in hemodialysis patients: a multicenter interventional study Effectiviteit van een mRNA-1273 booster vaccin tegen Covid-19 doorbraakinfecties bij hemodialyse patiënten: een multicentrische interventionele studie

Not yet recruiting
4
800
Europe
J07BX03, Concentrate and solvent for solution for injection, Spikevax (Moderna)
AZ Sint-Jan Brugge-Oostende AV, VZW Nierziekten en infectieziekten AZ Sint-Jan Brugge Oostende
hemodialysis patients hemodialyse patiënten, patients with renal failure requiring renal function replacement therapy (i.e. hemodialysis) patiënten met nierfalen die niervervangende therapie nodig hebben, Body processes [G] - Immune system processes [G12]
 
 
2021-004016-26: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection" "COVID-19 infektion taudinkuva, immuunivaste, genetiikka ja patogeneesi"- tutkimuksen alatutkimus "Koronarokotteen aikaan saama vaste"

Ongoing
4
1000
Europe
Comirnaty, Vaxzevria, Spikevax, Injection, Comirnaty, Vaxzevria, Spikevax
Meilahti Vaccine Research Center - Helsinki University Hospital
None, None, Body processes [G] - Immune system processes [G12]
 
 
2021-004419-14: COVID-19 infections in hospital personnel COVID-19 -infektiot sairaalahenkilökunnalla

Ongoing
4
1000
Europe
Concentrate and solvent for suspension for injection, Concentrate for solution for injection, Concentrate for dispersion for injection, Comirnaty, Vaxzevria, Spikevax
Turku University Hospital, Turku University Hospital, University of Turku, Jane and Aatos Erkko Foudation, The Academy of Finland
COVID-19 COVID-19, COVID-19 COVID-19, Body processes [G] - Immune system processes [G12]
 
 
2021-003710-39: COVID-19 :Immune response in patients with cancer undergoing vaccination against SARS-CoV-2

Not yet recruiting
4
525
Europe
COMIRNATY, SPIKEVAX, COMIRNATY Original/Omicron BA.1, SPIKEVAX bivalent Original/Omicron BA.1, COMIRNATY Original/Omicron BA.4-5, Spikevax bivalent Original/Omicron BA.4-5, Comirnaty Omicron XBB.1.5, Spikevax XBB 1.5, Concentrate for dispersion for injection, Dispersion for injection, COMIRNATY, SPIKEVAX, COMIRNATY Original/Omicron BA.1, SPIKEVAX bivalent Original/Omicron BA.1, Comirnaty Original/Omicron BA.4-5, Spikevax bivalent Original/Omicron BA.4-5, Comirnaty Original/Omicron XBB1.5, Spikevax XBB 1.5
INSTITUT JULES BORDET, ROCHE
adult cancer patients, adult cancer patients, Diseases [C] - Cancer [C04]
 
 
NCT05079633: A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

Completed
4
220
RoW
Homologous boost schedule, Heterologous boost schedule
National Taiwan University Hospital
Covid19 Vaccine
10/21
01/23
2021-006832-24: Hospital immunity after SARS-CoV-2 vaccination

Ongoing
4
2600
Europe
Corminaty, Spikevax, Vaxzevria, Concentrate for solution for injection, Comirnaty COVID-19 mRNA-vaccine, Spikevax COVID-19-mRNA vaccine, Vaxzevria COVID-19-vaccin (ChAdOx1-S [recombinant])
Ziekenhuis Oost-Limburg A.V., Ziekenhuis Oost-Limburg A.V., Roche Diagnostics International Ltd, Interreg Euregio Meuse-Rhine
efficiency and durability of the humoral immune response after vaccination against SARS-CoV-2, Immune response after vaccination against COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2022-000302-10: Measurement of immune response to vaccination against COVID19 of immunocompromised leukemic patients Stanovení odpovědi na očkování proti COVID19 u leukemických pacientů s oslabenou imunitou

Ongoing
4
30
RoW
Concentrate and solvent for solution for injection, Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), Spikevax COVID-19 Vaccine Moderna dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)
Institute of hematology and blood transfusion, Institute of hematology and blood transfusion
Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19 Příjemci buněčné terapie (allo-HSCT, CAR19 T buňky) indikovaní k očkování proti COVID19., Recipients of bone marrow or CAR T cells Příjemci po transplantaci kostní dřeně nebo CAR T buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04952402: SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Completed
4
43
US
Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, SARS-CoV2 Infection
02/22
01/23
2022-000905-29: Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies Cinetica tempoRale dei marcatori di risposta anticorpale e cEllulare e relativo impatto della rivacciNazione in pazienti guariti dalla COVID-19 dopo trattamento con anticoRpi monoclonali

Not yet recruiting
4
150
Europe
Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid, [-], Solution for injection, Concentrate for solution for infusion, Dispersion for injection, Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
Covid-19 infection Infezione da Covid-19, Covid-19 infection Infezione da Covid-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-004891-33: COVID-19 vaccine induced immune response in patients with primary antibody deficiency COVID-19 rokotuksen synnyttämät immuunivasteet primaarista vasta-ainepuutosta sairastavilla potilailla

Ongoing
4
50
Europe
Comirnaty, active substance tozinameran, Vaxzevria, active substance: adenovirus encoding SARS-CoV-2 virus spikeprotein ChAdOx1-S, Spikevax, active substance: elasomeran, Concentrate and solvent for suspension for injection, Concentrate and solvent for solution for injection, Concentrate for dispersion for injection, Comirnaty, Vaxzevria, Spikevax
Turku University Hospital, Turku University Hospital, University of Turku, Jane and Aatos Erkko Foundation, The Academy of Finland
COVID-19 COVID-19, COVID-19 COVID-19, Body processes [G] - Immune system processes [G12]
 
 
ACTRN12621001063808: A randomised control trial to evaluate the reactions of co-administration of influenza and COVID-19 vaccines

Suspended
4
1000
 
Sydney Local Health District, Sydney Local Health District, Snow Medical Research Foundation
Influenza, COVID-19
 
 
2021-001459-15: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus Immunantwort auf COVID-19 Impfung bei Personen mit Diabetes Mellitus

Not yet recruiting
4
160
Europe
COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine Janssen, EMEA/H/C/005675, EMEA/H/C/005735, EMEA/H/C/005791, EMEA/H/C/005737, Injection, COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 vaccine Moderna, COVID-19 Vaccine Janssen
Medical University of Graz, Medical University of Graz
Type 1 Diabetes MellitusType 2 Diabetes Mellitus Diabetes Mellitus Typ 1Diabetes Mellitus Typ 2, Type 1 Diabetes MellitusType 2 Diabetes Mellitus Diabetes Mellitus Typ 1Diabetes Mellitus Typ 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2021-000307-20: Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS)

Not yet recruiting
4
40
Europe
Kesimpta 20 mg Injektionslösung im Fertigpen, OMB157G, Solution for injection in pre-filled pen, Dispersion for injection, Kesimpta, Comirnaty Konzentrat zur Herstellung einer Injektionsdispersion, Spikevax
Novartis Pharma Vertriebs GmbH, Novartis Pharma GmbH
relapsing multiple sclerosis, relapsing multiple sclerosis treated with ofatumumab, Diseases [C] - Nervous System Diseases [C10]
 
 
I-SPARC, NCT05075538: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

Terminated
4
152
Europe
Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1, Spikevax bivalent Original/Omicron BA.4-5, Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4-5, Comirnaty Omicron XBB.1.5, Spikevax Omicron XBB.1.5
Jules Bordet Institute, Roche Pharma AG
Cancer
01/24
01/24
2021-006877-44: Factors that influence the formation of Corona-specific antibodies Faktoren welche die Entstehung von Corona-spezifischen Antikörpern beeinflussen können.

Not yet recruiting
4
2000
Europe
BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2-S, EMEA/H/C/005735, EMEA/H/C/005791, EMEA/H/C/005675, EMAE/H/C/005737, , Solution for injection/infusion, Solution for injection, BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2-S
Fachhochschule Salzburg GmbH, Fachhochschule Salzburg GmbH
Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with SARS-CoV-2 directed vaccins. Vorbeugung oder Linderung von Symptomen einer Covid-19 Erkrankung durch die Impfung mittels eines SARS-CoV-2 spezifischen Impfstoff., Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with Corona virus directed vaccins. Vorbeugung oder Linderung von Symptomen einer Covid-19 Erkrankung durch die Impfung mittels eines Corona Virus-spezifischen Impfstoff., Diseases [C] - Virus Diseases [C02]
 
 
NCT06441955: Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Recruiting
4
100
US
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Phramacotherapies, Physiological Evaluation, Immunologic Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Whole Genome Sequence, Multidisciplinary approach
Well- Konnect Healthcare Services and Research Firm, All of Us Research Program at the National Institute of Health
COVID-19, Long Haul
09/30
09/30
NCT06038617: Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

Recruiting
4
600
US
mRNA COVID-19 Vaccine, Pfizer COVID-19 Vaccine, Moderna COVID-19 Vaccine, Routine Childhood Vaccinations, Pneumococcal, DTaP, Haemophilus Influenzae Type B, MMR, Varicella, MMRV, Hepatitis A, Inactivated Poliovirus, Hepatitis B, Rotavirus, Influenza vaccines
Duke University, Kaiser Permanente, Columbia University, Children's Hospital Medical Center, Cincinnati, Centers for Disease Control and Prevention
Fever After Vaccination, Fever, Seizures Fever
07/25
12/25
NCT06585241: A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Adults to Prevent COVID-19

Active, not recruiting
4
100
US
mRNA-1273 Variant-containing Formulation
ModernaTX, Inc.
SARS-CoV-2
10/25
10/25
NCT06634797: A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Completed
4
1000
US
mRNA-1273.712, Placebo
ModernaTX, Inc.
Healthy Volunteers
01/25
01/25
NCT05212610: Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

Completed
4
103
US
Pfizer-BioNTech mRNA COVID-19 vaccine, Comirnaty
University of Michigan, The Wallace Foundation
COVID-19, Corona Virus Infection
03/25
03/25
COVIAAD, NCT04806113: COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

Completed
3
220
Canada
Moderna COVID-19 vaccine
McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval, Ministere de la Sante et des Services Sociaux
Covid19, Rheumatic Diseases, Rheumatoid Arthritis, SLE
06/21
06/22
REIN-TX, NCT05048940: Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.

Withdrawn
3
386
Europe
Janssen vaccine, Janssen Biologics B.V., EU/1/20/1525/001 EU/1/20/1525/002, Spikevax (Moderna) vaccine, MODERNA BIOTECH SPAIN, S.L., EU/1/20/1507/001
Instituto de Investigación Marqués de Valdecilla
Covid19
09/21
09/21
COVALL, NCT05028257: Allergy and COVID-19 Vaccines

Completed
3
117
Europe
COVID-19 Vaccines, Janssen COVID19 vaccine, Astra Zeneca COVID19 vaccine, Comirnaty Pfizer COVID19 vaccine, Moderna COVID19 vaccine
Assistance Publique - Hôpitaux de Paris
Anaphylactic Reaction, Vaccine Reaction
05/23
05/23
NCT05230953: Fourth COVID-19 Vaccine Dose- mRNA1273

Active, not recruiting
3
1000
RoW
mRNA1273 vaccine
Sheba Medical Center
COVID-19 Pandemic
07/24
07/24
MIACoV, NCT05228730: Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus ().

Terminated
3
13
RoW
Tozinameran - Standard dose, BNT162b2, Pfizer-BioNTech, Comirnaty, Tozinameran - fractional dose, Elasomeran - standard dose, mRNA-1273, Spikevax, Moderna, Elasomeran - fractional dose
Murdoch Childrens Research Institute, Coalition for Epidemic Preparedness Innovations, The Peter Doherty Institute for Infection and Immunity
COVID-19
07/22
11/22
SCTV01C-E-01-UAE-1, NCT05323461: A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

Active, not recruiting
3
1800
RoW
SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine, Comirnaty
Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
10/22
05/23
NCT05158140: Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Completed
3
850
US
V110, PNEUMOVAX™23, 23-Valent Pneumococcal Polysaccharide Vaccine, V114, VAXNEUVANCE™, 15-Valent Pneumococcal Conjugate, Vaccine, mRNA-1273, Placebo for V110, Placebo for V114
Merck Sharp & Dohme LLC
Pneumococcal Infection
02/23
02/23
NCT04860297: A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Completed
3
234
US
mRNA-1273
ModernaTX, Inc.
SARS-CoV-2
05/23
05/23
COVERALL, NCT04805125: Immunocompromised Swiss Cohorts Based Trial Platform

Completed
3
610
Europe
Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)
University Hospital, Basel, Switzerland, Swiss National Science Foundation, ModernaTX, Inc.
Immunocompromised Patients
09/23
09/23
V503-076, NCT05119855 / 2021-003591-13: Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine

Completed
3
165
US
9vHPV Vaccine, V503, GARDASIL®9, SILGARD®9, mRNA-1273 Vaccine, SARS-CoV-2 Vaccine, Moderna COVID-19 Vaccine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Papillomavirus Infections, Coronavirus Disease (COVID-19)
12/23
12/23
NCT05556720: Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Recruiting
3
960
RoW
Pfizer Bivalent COVID-19 Vaccine, Pfizer-BioNTech bivalent mRNA vaccine, COMIRNATY Original/Omicron BA.1, Moderna Bivalent mRNA vaccine, Moderna Bivalent Original/Omicron, Elasomeran/imelasomeran, Spikevax
Bayside Health, Monash University
HIV, Organ Transplantation, Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia, Multiple Myeloma, COVID-19 Vaccines
02/24
12/25
2023-000884-30: A Study of mRNA-1283 Compared with mRNA-1273 in Participants ≥12 Years of Age to Prevent COVID-19

Not yet recruiting
3
33574
Canada, Europe, US
mRNA-1283, mRNA-1273, Injection
ModernaTX, Inc., ModernaTX, Inc.
COVID-19, Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
RSVictory, NCT05330975: A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Completed
3
3317
US
Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
ModernaTX, Inc.
Respiratory Syncytial Virus
11/24
11/24
NCT06354998: A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

Completed
3
215
RoW
Investigational mRNA-1273.815, Licensed Spikevax Vaccine
ModernaTX, Inc.
SARS-CoV-2
05/24
05/24
2021-003591-13: Safety and Immunogenicity of 9vHPV Vaccine Coadministered With mRNA-1273 SARS-CoV-2 Vaccine

Not yet recruiting
3
160
US
Suspension for injection, Dispersion for injection, GARDASIL®9 (9vHPV vaccine), mRNA-1273 SARS-CoV-2 vaccine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Papilloma viral infection, Papilloma viral infection, Body processes [G] - Immune system processes [G12]
 
 
2024-000165-25: A Study to Evaluate the Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Not yet recruiting
3
1860
RoW, US
mRNA-1273.214, mRNA-1273.815, Injection
ModernaTX, Inc., ModernaTX, Inc.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT05436834 / 2024-000165-25: A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Recruiting
3
1860
US, RoW
mRNA-1273.214, mRNA-1273.815
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2
10/25
10/25
NextCOVE, NCT05815498 / 2023-000884-30: A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

Completed
3
14246
Europe, Canada, Japan, US
mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815
ModernaTX, Inc., ModernaTX, Inc.
COVID-19
04/25
04/25
NCT06694389: Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Recruiting
3
2450
Japan, RoW
mRNA-1083, Placebo, Licensed Influenza Vaccine, Influenza HA, Biken, and, Fluarix tetra, SARS-CoV-2 Vaccine, mRNA-1273
ModernaTX, Inc.
COVID-19, Influenza
12/25
12/25
NCT05387317: Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)

Withdrawn
3
800
RoW
Pfizer-BioNTech Standard dose, BNT162b2, Comirnaty, AstraZeneca Standard dose, ChAdOx1-S, Vaxzevria, Pfizer-BioNTech Fractional dose, AstraZeneca Fractional dose, Moderna Standard dose, mRNA-1273, Spikevax®, Moderna Fractional dose
Murdoch Childrens Research Institute, Universitas Padjadjaran, Health Development Policy Agency, Ministry of Health Republic of Indonesia, Coalition for Epidemic Preparedness Innovations, The Peter Doherty Institute for Infection and Immunity, Indonesia University
COVID-19
01/25
10/25
BOOST KIDNEY, NCT05022329: COVID-19 Vaccine Boosters in Patients With CKD

Terminated
2/3
273
Canada
Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 mRNA COVID-19 Vaccine, MODERNA SARS-CoV-2 Vaccine, mRNA-1273 SARS-CoV-2 Vaccine
Sunnybrook Health Sciences Centre, University Health Network, Toronto, Unity Health Toronto, Scarborough General Hospital, Providence Healthcare
Chronic Kidney Diseases, COVID-19
05/22
11/22
NCT05279365: PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

Recruiting
2/3
1000
US
Pfizer/BioNTech (BNT162b2), Moderna
DHR Health Institute for Research and Development
SARS CoV 2 Infection, COVID-19
08/22
08/23
NCT05249829 / 2022-000063-51: A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

Completed
2/3
3548
Europe
mRNA-1273.529, mRNA-1273, mRNA-1273.214
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2
06/23
06/23
CoVPN3008, NCT05168813: Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Completed
2/3
14232
RoW
Moderna mRNA-1273, Vaccine 3 Dose, Vaccine 2 Dose
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
SARS-CoV-2 Infection, HIV Infections, COVID-19
04/24
04/24
2023-000382-14: A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Not yet recruiting
2/3
4440
RoW, US
mRNA-1273, mRNA-1273.222, Injection, Spikevax
ModernaTX, Inc., ModernaTX, Inc., Biomedical Advanced Research and Development Authority
Coronavirus Disease 2019, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2022-000063-51: A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

Not yet recruiting
2/3
3924
Europe
mRNA-1273.529, mRNA-1273.214, mRNA-1273, Injection
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2, Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT04796896 / 2021-000281-15: A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Completed
2/3
11950
Canada, US
mRNA-1273, Placebo, mRNA-1273.214
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2
03/24
03/24
TeenCove, NCT04649151 / 2023-000382-14: A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Completed
2/3
4331
US, RoW
mRNA-1273, Placebo, mRNA-1273.222
ModernaTX, Inc., Biomedical Advanced Research and Development Authority
SARS-CoV-2
06/24
06/24
2021-002927-39: Preventive strategies against SARS-CoV-2 in kidney transplant recipients:Intervention A - vaccination: Study to test if vaccination with Ad26COVS1 or ChAdOx1-S results in a better immune response compared to a third dose of BNT162b2 or mRNA-1273 in kidney transplant recipients who did not develop an immune response following previous vaccination against COVID-19Intervention B - monoclonal SARS-CoV-2 antibody cocktail in kidney transplant recipients not responding to vaccination

Not yet recruiting
2
400
Europe
EVUSHELD, AZD7442, Suspension for injection, Concentrate for dispersion for injection, Dispersion for injection, Lyophilisate for solution for injection, COVID-19 Vaccine Janssen, Comirnaty, COVID-19 Vaccine Moderna, Vaxzevria
Medical University of Vienna, Medical University of Vienna
Intervention A - vaccinationPatients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccineSubstudy A: kidney transplant recipients who did not develop antibodies after a fourth doseIntervention B - monoclonal antibodiesKidney transpant recipients who do not develop neutralizing antibodies after at least two doses of SARS-CoV-2 vaccine, Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following vaccination, Diseases [C] - Immune System Diseases [C20]
 
 
CoviCompareM, NCT04748471: Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)

Not yet recruiting
2
180
NA
mRNA-1273
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Prevention of COVID19
07/21
01/23
NCT05027672: Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.

Active, not recruiting
2
348
RoW
Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5), Gam-COVID-Vac (rAd26) / ChAdOx1 nCoV-19, Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd26), Gam-COVID-Vac (rAd26) / mARN-1273
Ministerio de Salud de Ciudad Autónoma de Buenos Aires
COVID-19 Vaccines
08/21
09/21
2021-002356-37: Study about the response to the administration of a third dose of mRNA-1273 vaccine (COVID19 vaccine Moderna) in renal transplants with immunological failure initial to vaccination ESTUDIO SOBRE LA RESPUESTA A LA ADMINISTRACIÓN DE UNA TERCERA DOSIS DE LA VACUNA mRNA-1273 (COVID19 Vaccine Moderna) EN TRASPLANTADOS RENALES CON FRACASO INMUNOLÓGICO INICIAL A LA VACUNACION

Ongoing
2
80
Europe
COVID-19 Vaccine Moderna dispersion for injection
Fundació Clinic per a la Recerca Biomèdica (FCRB), Fundació Clinic per a la Recerca Biomèdica (FCRB)
COVID19 vaccine in kidney transplant patients Vacuna COVID19 en pacientes trasplantados renales, COVID19 vaccine in kidney transplant patients Vacuna COVID19 en pacientes trasplantados renales, Diseases [C] - Virus Diseases [C02]
 
 
ECEHeVac, NCT04988048: Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina

Recruiting
2
1760
RoW
COVID-19 vaccines, SPUTNIK-V (Gam-COVID-Vac), SINOPHARM (BBIBP-CorV), AstraZeneca (ChAdOx1 nCoV-19 vaccine AZD1222), Moderna (mRNA-1273 or Spikevax)
Ministry of Public Health, Argentina, Russian Direct Investment Fund
COVID-19 VACCINE, Covid19
09/21
02/22
2021-004526-29: A multinational, phase 2, randomised, adaptive protocol to assess immune response and side effects of different COVID-19 vaccines given in older adults (75 years and older) already vaccinated against SARS-CoV-2

Ongoing
2
600
Europe
Spikevax, Concentrate for dispersion for injection, Dispersion for injection, Comirnaty, Spikevax
University of Cologne, European Commission
Prevention of COVID-19 infection, Prevention of COVID-19 infection, Body processes [G] - Immune system processes [G12]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
intismeran autogene (mRNA-4157) / Merck (MSD), Moderna
INTerpath-009, NCT06623422: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/)

Recruiting
3
680
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, Platinol®, Platinol®-AQ, Carboplatin, Paraplatin®, Pemetrexed, Alimta®, Gemcitabine, Gemzar, Paclitaxel, Taxol®, Onxol®, Intismeran autogene, mRNA-4157, V940, Placebo
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Carcinoma, Non-Small-Cell Lung
05/33
01/38
INTerpath-001, NCT05933577: A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Active, not recruiting
3
1089
Europe, Canada, Japan, US, RoW
Intismeran autogene, mRNA-4157, Individualized neoantigen therapy, V940, Pembrolizumab, MK-3475, Keytruda®, Placebo, Normal saline, Dextrose
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Melanoma
10/29
09/30
INTerpath-002, NCT06077760: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Recruiting
3
868
Europe, Canada, Japan, US, RoW
Intismeran autogene, mRNA-4157, V940, Pembrolizumab, MK-3475, KEYTRUDA®, Placebo
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Non-small Cell Lung Cancer
06/30
12/35
INTerpath-007, NCT06295809: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007).

Active, not recruiting
2/3
1012
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Intismeran autogene, mRNA-4157, V940, Surgery
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Carcinoma, Squamous Cell, Skin Neoplasms
03/26
03/26
INTerpath-004, NCT06307431: A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Active, not recruiting
2
272
Europe, Canada, US, RoW
Intismeran autogene, mRNA-4157, V940, Pembrolizumab, MK-3475, KEYTRUDA®, Placebo
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Renal Cell Carcinoma
01/28
06/32
INTerpath-011, NCT06833073: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/)

Recruiting
2
308
US, RoW
Intismeran autogene, mRNA-4157, V940, BCG, BCG Live, TICE®, TheraCys®
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
09/31
09/31
INTerpath-012, NCT06961006: A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/)

Not yet recruiting
2
160
NA
V940, mRNA-4157, Pembrolizumab, MK-3475, KEYTRUDA®, Placebo
Merck Sharp & Dohme LLC
Malignant Melanoma
07/28
09/31
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
INTerpath-005, NCT06305767: A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/)

Recruiting
1/2
230
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Intismeran autogene, V940, Placebo, Enfortumab Vedotin, PADCEV®, Surgery (RC plus PLND)
Merck Sharp & Dohme LLC, ModernaTX, Inc.
Bladder Cancer
04/27
10/31
KEYNOTE-603, NCT03313778: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Recruiting
1
242
Europe, Japan, US, RoW
mRNA-4157, Pembrolizumab, SoC Treatment, Standard of care chemotherapy
ModernaTX, Inc., Merck Sharp & Dohme LLC
Solid Tumors
06/25
06/25
VX-522 / Vertex, Moderna
VX21-522-001, NCT05668741: A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Recruiting
1/2
33
Europe, Canada, US, RoW
VX-522 mRNA therapy, IVA, ivacaftor, VX-770
Vertex Pharmaceuticals Incorporated, Moderna, Inc
Cystic Fibrosis
03/25
03/25
mRNA-2752 / Moderna
NCT02872025: Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

Active, not recruiting
1
42
US
Pembrolizumab, Keytruda, MK-3475, Intralesional mRNA 2752, mRNA 2752
Laura Esserman, Merck Sharp & Dohme LLC, ModernaTX, Inc.
Carcinoma, Intraductal, Noninfiltrating
03/26
03/26
mRNA-2752-P101, NCT03739931: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Checkmark Data in combination with mRNA-2752 in solid tumors and lymphomas at SITC 2021
Nov 2021 - Nov 2021: Data in combination with mRNA-2752 in solid tumors and lymphomas at SITC 2021
Active, not recruiting
1
134
US, RoW
mRNA-2752, Durvalumab
ModernaTX, Inc., AstraZeneca
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
12/25
12/25
MEDI1191 / Moderna
D8510C00001, NCT03946800: A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Completed
1
61
Europe, US
MEDI1191, Durvalumab
MedImmune LLC
Solid Tumors, Cancer
08/23
08/23
mRNA-1644 / Moderna
NCT05001373: A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Active, not recruiting
1
56
US
Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
International AIDS Vaccine Initiative, ModernaTX, Inc., George Washington University, Fred Hutchinson Cancer Center, Emory University, UT Health San Antonio
Hiv
06/23
07/24
NCT05414786: A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

Active, not recruiting
1
18
RoW
eOD-GT8 60mer mRNA Vaccine (100µg)
International AIDS Vaccine Initiative, AURUM Tembisa Clinical Research, Center for Family Health Research, ModernaTX, Inc.
HIV-1-infection
06/23
06/23
mRNA-3927 / Moderna
2019-003529-36: A clinical study to evaluate the medicinal product in Patients with Propionic Acidemia

Not yet recruiting
1/2
36
Europe
mRNA-3927, Injection
ModernaTX, Inc, ModernaTX, Inc.
Propionic Acidemia- Propionic acidemia is an autosomal recessive disorder caused by loss-of-function mutations in PCCA or PCCB (and in rare instances, mutations in both PCCA and PCCB), resulting in the loss of enzymatic activity of the mitochondrial complex PCC, Deficiency of PCCA and PCCB, Body processes [G] - Metabolic Phenomena [G03]
 
 
mRNA-3927-P101, NCT04159103 / 2019-003529-36: Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Recruiting
1/2
68
Europe, Canada, Japan, US
mRNA-3927
ModernaTX, Inc., ModernaTX, Inc.
Propionic Acidemia
01/26
01/26
NCT05130437: A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Recruiting
1/2
36
Europe, Canada, US
mRNA-3927
ModernaTX, Inc.
Propionic Acidemia
12/29
12/31
mRNA-1647 / Moderna
NCT05085366 / 2020-006051-17: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Active, not recruiting
3
7454
Europe, Canada, Japan, US, RoW
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
04/26
04/28
NCT06133010: A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Withdrawn
2
342
NA
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
02/27
12/27
NCT05683457: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Recruiting
2
224
US
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
08/26
08/26
NCT04975893: A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Enrolling by invitation
2
291
US
mRNA-1647
ModernaTX, Inc.
Cytomegalovirus Infection
12/26
12/26
2022-001545-20: A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Not yet recruiting
1/2
770
Canada, Europe, US
mRNA-1647, mRNA-1647, Injection
ModernaTX, Inc., ModernaTX, Inc.
Cytomegalovirus infection, Cytomegalovirus infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT05575492 / 2022-001545-20: A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Recruiting
1/2
770
Europe, Canada, US
mRNA-1647, Placebo
ModernaTX, Inc., ModernaTX, Inc.
Cytomegalovirus
01/27
01/27
NCT05105048: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

Completed
1
9
US
mRNA-1647, Placebo
ModernaTX, Inc.
Cytomegalovirus Infection
08/23
08/23
NCT05397223: A Study of Modified mRNA Vaccines in Healthy Adults

Active, not recruiting
1
308
US
mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
ModernaTX, Inc.
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
02/26
02/26
Spikevax (elasomeran) / Moderna
2021-004788-29: COVID-19 vaccine immunology Koronarokoteimmunologia

Ongoing
4
4000
Europe
Concentrate for dispersion for injection, Dispersion for injection, Suspension for injection, , Comirnaty, Spikevax, Vaxzevria, Tutkimuksen kohteena ovat Suomen kansallisen koronarokoteohjelman tarjoamat COVID-19 rokotteet. Tämä koskee myös tutkimuksen aikana tällaiseen käyttöön tulevia COVID-19 rokotteita, mukaan lukien yhdistelmärokotteet.
Finnish Institute for Health and Welfare, Finnish Institute for Health and Welfare
Tutkittavat ovat terveitä (Immuniteetti COVID-19 infektiota vastaan), Tutkittavat ovat terveitä (Immuniteetti COVID-19 infektiota vastaan), Body processes [G] - Immune system processes [G12]
 
 
ACTRN12622000238774: A randomised trial to evaluate the immune response of COVID-19 vaccines in adults and adolescents

Recruiting
4
1325
 
The Kids Research Institute Australia, National Health and Medical Research Council (NHMRC), Snow Medical Research Foundation
COVID-19
 
 
2021-001054-57: SARS-CoV-2 vaccination study in people living with HIV SARS-CoV-2 vaccinatie studie in mensen die leven met HIV

Ongoing
4
1650
Europe
COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine (ChAdOx1-S [recombinant]), EMEA/H/C/005791, EMEA/H/C/005735, EMEA/H/C/005675, Dispersion for injection, Concentrate for dispersion for infusion, Suspension for injection, COVID-19 Vaccine Moderna, Comirnaty, COVID-19 Vaccine AstraZeneca
OLVG, ZonMW
COVID-19 vaccine response in people living with HIV COVID-19 vaccinatie respons in mensen die leven met HIV, COVID-19 vaccination effect in people living with HIV COVID-19 vaccinatie effect in mensen die leven met HIV, Diseases [C] - Virus Diseases [C02]
 
 
2021-000206-17: Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. Studier av pågående och genomgången SARS-CoV-2 infektion (som orsakar COVID-19) inom vård och omsorg i Stockholms län, med avseende på vaccinationer.

Ongoing
4
10000
Europe
Concentrate for solution for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Karolinska University Hospital, Karolinska University Hospital
Vaccination against COVID-19. Vaccination mot COVID-19., Vaccination against COVID-19. Vaccination mot COVID-19., Diseases [C] - Virus Diseases [C02]
 
 
2021-000710-42: Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC study) Onderzoek naar het effect van de COVID-vaccinatie bij patiënten die behandeld worden met rituximab (de RTX-COVAC studie).

Ongoing
4
270
Europe
COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, Concentrate for solution for injection, Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Sint Maartenskliniek, Sint Maartenskliniek
Rheumatoid arthritis Reumatoïde artritis, Rheumatic disease Reuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2021-000440-22: Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium

Ongoing
4
420
Europe
Comirnaty, Covid19 Vaccine Moderna, Covid 19 Vaccine AstraZeneca, J07BX03, Injection, Comirnaty, Covid-19 Vaccine Moderna, COVID19 Vaccine Astrazeneca
Universiteit Antwerpen, Sciensano
Vaccine responses to COVID19 vaccines administered in pregnant andlactating women, Corona virus vaccine responses in pregnant and lactating women, Diseases [C] - Virus Diseases [C02]
 
 
2021-000349-42: Evaluation of How Long Immune Responses to SARS-CoV-2 Persist Following COVID-19 Vaccination

Ongoing
4
500
Europe
Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Sahlgrenska Academy, University of Gothenburg
COVID-19, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-000905-26: Response to Covid-19 vaccination in patients with cancer

Ongoing
4
150
Europe
Concentrate for dispersion for infusion, Concentrate for solution for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Department of Oncology, Uppsala University Hospita, Department of Oncology, Uppsala University Hospital
Immune response to Covid-19 vaccination of patients with immune modulatory treatment for cancer, Response to Covid-19 vaccination in patients with treatment for cancer, Body processes [G] - Immune system processes [G12]
 
 
2021-001769-19: Immune response to SARS-CoV-2 in health care workers, previously infected subjects, and immunocompromised subjects, before and after Covid-19 vaccination: a phase IV trial

Ongoing
4
1200
Europe
Injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, COVID-19 Vaccine Janssen
GUVAX (Gothenburg University Vaccine Research Institute), SciLife
SARS-COV-2 infection, Coronavirus disease, Diseases [C] - Virus Diseases [C02]
 
 
2021-002014-14: Monitoring of antibody response 28 days after the first dose of COVID19 vaccine in clinically stable subjects with functional kidney transplantation. Sledování protilátkové odpovědi v intervalu 28 dní po první dávce vakcíny proti COVID19 u klinicky stabilních osob s funkční transplantovanou ledvinou.

Ongoing
4
60
RoW
Fakultní nemocnice Hradec Králové, Hemodialyzační středisko Fakultní nemocnice Hradec Králové
Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) in clinically stable patients with functional kidney transplantation. Protilátková a buněčná odpověď v odstupu 28 dní po podání první dávky COVID-19 vakcíny (Moderna) u klinicky stabilních pacientů s funkční transplantovanou ledvinou., Monitoring of antibody response 28 days after the first dose of COVID19 vaccine in clinically stable subjects with functional kidney transplantation. Sledování protilátkové odpovědi v intervalu 28 dní po první dávce vakcíny proti COVID19 u klinicky stabilních osob s funkční transplantovanou ledvinou., Body processes [G] - Immune system processes [G12]
 
 
2021-001993-52: Immunogenicity after COVID-19 vaccines in adapted schedules

Not yet recruiting
4
560
Europe
Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, Vaxzevria
University of Antwerp, Belgian Health Care Knowledge Centre (KCE)
Coronavirus disease-19 (COVID-19), COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-001976-40: SARS-Cov-2 vaccine responsiveness in middle-aged and older persons

Not yet recruiting
4
1700
Europe
Suspension for injection, Comirnaty, Spikevax, Vaxzevria, COVID-19 Vaccine Janssen
National Institute for Public Health and the Environment, National Institute for Public Health and the Environment
SARS-CoV-19, frailty, COVID-19, frailty, Body processes [G] - Immune system processes [G12]
 
 
IMCOVAS, NCT06189040: Immunogenicity After COVID-19 Vaccines in Adapted Schedules

Completed
4
580
Europe
BNT162b2 30µg, BNT162b2 20µg, BNT162b2 6µg, mRNA-1273 100µg, mRNA-1273 50µg, ChAdOx1-S [Recombinant]
Universiteit Antwerpen
Coronavirus Disease 2019, COVID-19
11/21
07/22
2021-002363-22: Vaccination of older persons against SARS-CoV2 and inducing cellular immunity

Not yet recruiting
4
150
Europe
Suspension for injection, Comirnaty, Spikevax, Vaxzevria, COVID-19 Vaccine Janssen
National Institute for Public Health and the Environment, National Institute for Public Health and the Environment
SARS-CoV-19, frailty, COVID-19, frailty, Body processes [G] - Immune system processes [G12]
 
 
2021-002613-34: Effectivity of COVID-19 vaccination in people with Down syndrome

Ongoing
4
640
Europe
Concentrate for dispersion for injection, Dispersion for injection, Suspension for injection, Comirnaty COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine Moderna, Vaxzevria
University Medical Center Utrecht, ZonMw
Persons with Down syndrome, Persons with Down syndrome, Body processes [G] - Immune system processes [G12]
 
 
2021-003618-37: Booster dose of SARS-CoV-2 vaccine to patients with suboptimal response to previous doses.

Ongoing
4
1000
Europe
SARS-CoV-2 mRNA, Concentrate for dispersion for injection, Concentrate and solvent for solution for injection, Comirnaty, Spikevax
Oslo University Hospital, Oslo University Hospital
Patients with immune deficiency without proper response to previous SARS-CoV-2 vaccine doses., Vaccination for protection against COVID-19, Diseases [C] - Immune System Diseases [C20]
 
 
2021-003386-35: Vaccination for Recovered Inpatients with COVID-19 (VATICO) Vacunación para pacientes hospitalizados recuperados con COVID-19 (VATICO)

Ongoing
4
640
Europe
Concentrate for solution for injection, COMIRNATY concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), Spikevax dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)
Regents of the University of Minesota, National Insitute of Health
Participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still [TICO assignment] blinded, and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups of the Moderna mRNA 1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines) Los participantes del ens. clín. ACTIV-3/TICO en los centros seleccionados que recibieron agentes en investigación ciegos o placebo preespecificados como parte de ese ensayo, y que han logrado una recuperación sostenida, y que todavía están [asignación de TICO] cegados, y que todavía están dentro de los 28 a 90 días después de la aleatoriz. inicial de TICO, serán aleatorizados en este diseño factorial 2x2 a uno de los cuatro grupos de la vacuna Moderna mRNA 1273 o Pfizer BNT162b2 (vac. de ARNm), Same as above Igual que arriba, Health Care [N] - Environment and Public Health [N06]
 
 
ACTRN12622001106729: Safety and efficacy of the 3rd and the 4th dose of mRNA COVID19 vaccine in kidney transplant recipients

Completed
4
140
 
Martin Kacer, Fighting INfectious Diseases "FIND"; Ministry of Education, Youth and Sports of the Czech Republic, Cooperatio; Charles University in Prague
COVID19 vaccination response, Kidney transplant recipients
 
 
2021-004558-44: Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients Optimale booster strategie voor SARS-CoV-2 vaccinatie in niertransplantatie patiënten.

Ongoing
4
460
Europe
Solution for injection, Spikevax, COVID-19 Vaccine Janssen
UMCG, ZonMW
COVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate mofetil (MMF) / mycophenolic acid (MPA). COVID-19 is geassocieerd met ernstig vergroot risico op ziekte en mortaliteit in niertransplantatie patiënten. Beschikbare data laat zien dat de immuunrespons na een standaard programma van 2 mRNA vaccinaties ernstig lager is in niertransplantatie patienten dan in een controle groep, zeker wanneer hun immuunsuppressie therapie MMF/MPA bevat., Many kidneytransplant patients are none responsive to the current Covid-19 vaccination regime. Therefore it is important to know whether a booster vaccine will increase the efficacy of vaccination. Veel niertransplantatie patienten hebben geen respons op het huidige Covid-19 vaccinatie beleid. Het is daarom van belang om te weten of een booster vaccin de effectiviteit van vaccinatie vergroot., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-004608-17: Effectivity of a mRNA-1273 booster vaccine against Covid-19 breakthrough infections in hemodialysis patients: a multicenter interventional study Effectiviteit van een mRNA-1273 booster vaccin tegen Covid-19 doorbraakinfecties bij hemodialyse patiënten: een multicentrische interventionele studie

Not yet recruiting
4
800
Europe
J07BX03, Concentrate and solvent for solution for injection, Spikevax (Moderna)
AZ Sint-Jan Brugge-Oostende AV, VZW Nierziekten en infectieziekten AZ Sint-Jan Brugge Oostende
hemodialysis patients hemodialyse patiënten, patients with renal failure requiring renal function replacement therapy (i.e. hemodialysis) patiënten met nierfalen die niervervangende therapie nodig hebben, Body processes [G] - Immune system processes [G12]
 
 
2021-004016-26: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection" "COVID-19 infektion taudinkuva, immuunivaste, genetiikka ja patogeneesi"- tutkimuksen alatutkimus "Koronarokotteen aikaan saama vaste"

Ongoing
4
1000
Europe
Comirnaty, Vaxzevria, Spikevax, Injection, Comirnaty, Vaxzevria, Spikevax
Meilahti Vaccine Research Center - Helsinki University Hospital
None, None, Body processes [G] - Immune system processes [G12]
 
 
2021-004419-14: COVID-19 infections in hospital personnel COVID-19 -infektiot sairaalahenkilökunnalla

Ongoing
4
1000
Europe
Concentrate and solvent for suspension for injection, Concentrate for solution for injection, Concentrate for dispersion for injection, Comirnaty, Vaxzevria, Spikevax
Turku University Hospital, Turku University Hospital, University of Turku, Jane and Aatos Erkko Foudation, The Academy of Finland
COVID-19 COVID-19, COVID-19 COVID-19, Body processes [G] - Immune system processes [G12]
 
 
2021-003710-39: COVID-19 :Immune response in patients with cancer undergoing vaccination against SARS-CoV-2

Not yet recruiting
4
525
Europe
COMIRNATY, SPIKEVAX, COMIRNATY Original/Omicron BA.1, SPIKEVAX bivalent Original/Omicron BA.1, COMIRNATY Original/Omicron BA.4-5, Spikevax bivalent Original/Omicron BA.4-5, Comirnaty Omicron XBB.1.5, Spikevax XBB 1.5, Concentrate for dispersion for injection, Dispersion for injection, COMIRNATY, SPIKEVAX, COMIRNATY Original/Omicron BA.1, SPIKEVAX bivalent Original/Omicron BA.1, Comirnaty Original/Omicron BA.4-5, Spikevax bivalent Original/Omicron BA.4-5, Comirnaty Original/Omicron XBB1.5, Spikevax XBB 1.5
INSTITUT JULES BORDET, ROCHE
adult cancer patients, adult cancer patients, Diseases [C] - Cancer [C04]
 
 
NCT05079633: A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

Completed
4
220
RoW
Homologous boost schedule, Heterologous boost schedule
National Taiwan University Hospital
Covid19 Vaccine
10/21
01/23
2021-006832-24: Hospital immunity after SARS-CoV-2 vaccination

Ongoing
4
2600
Europe
Corminaty, Spikevax, Vaxzevria, Concentrate for solution for injection, Comirnaty COVID-19 mRNA-vaccine, Spikevax COVID-19-mRNA vaccine, Vaxzevria COVID-19-vaccin (ChAdOx1-S [recombinant])
Ziekenhuis Oost-Limburg A.V., Ziekenhuis Oost-Limburg A.V., Roche Diagnostics International Ltd, Interreg Euregio Meuse-Rhine
efficiency and durability of the humoral immune response after vaccination against SARS-CoV-2, Immune response after vaccination against COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2022-000302-10: Measurement of immune response to vaccination against COVID19 of immunocompromised leukemic patients Stanovení odpovědi na očkování proti COVID19 u leukemických pacientů s oslabenou imunitou

Ongoing
4
30
RoW
Concentrate and solvent for solution for injection, Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), Spikevax COVID-19 Vaccine Moderna dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)
Institute of hematology and blood transfusion, Institute of hematology and blood transfusion
Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19 Příjemci buněčné terapie (allo-HSCT, CAR19 T buňky) indikovaní k očkování proti COVID19., Recipients of bone marrow or CAR T cells Příjemci po transplantaci kostní dřeně nebo CAR T buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04952402: SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Completed
4
43
US
Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, SARS-CoV2 Infection
02/22
01/23
2022-000905-29: Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies Cinetica tempoRale dei marcatori di risposta anticorpale e cEllulare e relativo impatto della rivacciNazione in pazienti guariti dalla COVID-19 dopo trattamento con anticoRpi monoclonali

Not yet recruiting
4
150
Europe
Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid, [-], Solution for injection, Concentrate for solution for infusion, Dispersion for injection, Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
Covid-19 infection Infezione da Covid-19, Covid-19 infection Infezione da Covid-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-004891-33: COVID-19 vaccine induced immune response in patients with primary antibody deficiency COVID-19 rokotuksen synnyttämät immuunivasteet primaarista vasta-ainepuutosta sairastavilla potilailla

Ongoing
4
50
Europe
Comirnaty, active substance tozinameran, Vaxzevria, active substance: adenovirus encoding SARS-CoV-2 virus spikeprotein ChAdOx1-S, Spikevax, active substance: elasomeran, Concentrate and solvent for suspension for injection, Concentrate and solvent for solution for injection, Concentrate for dispersion for injection, Comirnaty, Vaxzevria, Spikevax
Turku University Hospital, Turku University Hospital, University of Turku, Jane and Aatos Erkko Foundation, The Academy of Finland
COVID-19 COVID-19, COVID-19 COVID-19, Body processes [G] - Immune system processes [G12]
 
 
ACTRN12621001063808: A randomised control trial to evaluate the reactions of co-administration of influenza and COVID-19 vaccines

Suspended
4
1000
 
Sydney Local Health District, Sydney Local Health District, Snow Medical Research Foundation
Influenza, COVID-19
 
 
2021-001459-15: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus Immunantwort auf COVID-19 Impfung bei Personen mit Diabetes Mellitus

Not yet recruiting
4
160
Europe
COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine Janssen, EMEA/H/C/005675, EMEA/H/C/005735, EMEA/H/C/005791, EMEA/H/C/005737, Injection, COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 vaccine Moderna, COVID-19 Vaccine Janssen
Medical University of Graz, Medical University of Graz
Type 1 Diabetes MellitusType 2 Diabetes Mellitus Diabetes Mellitus Typ 1Diabetes Mellitus Typ 2, Type 1 Diabetes MellitusType 2 Diabetes Mellitus Diabetes Mellitus Typ 1Diabetes Mellitus Typ 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2021-000307-20: Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS)

Not yet recruiting
4
40
Europe
Kesimpta 20 mg Injektionslösung im Fertigpen, OMB157G, Solution for injection in pre-filled pen, Dispersion for injection, Kesimpta, Comirnaty Konzentrat zur Herstellung einer Injektionsdispersion, Spikevax
Novartis Pharma Vertriebs GmbH, Novartis Pharma GmbH
relapsing multiple sclerosis, relapsing multiple sclerosis treated with ofatumumab, Diseases [C] - Nervous System Diseases [C10]
 
 
I-SPARC, NCT05075538: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

Terminated
4
152
Europe
Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1, Spikevax bivalent Original/Omicron BA.4-5, Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4-5, Comirnaty Omicron XBB.1.5, Spikevax Omicron XBB.1.5
Jules Bordet Institute, Roche Pharma AG
Cancer
01/24
01/24
2021-006877-44: Factors that influence the formation of Corona-specific antibodies Faktoren welche die Entstehung von Corona-spezifischen Antikörpern beeinflussen können.

Not yet recruiting
4
2000
Europe
BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2-S, EMEA/H/C/005735, EMEA/H/C/005791, EMEA/H/C/005675, EMAE/H/C/005737, , Solution for injection/infusion, Solution for injection, BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2-S
Fachhochschule Salzburg GmbH, Fachhochschule Salzburg GmbH
Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with SARS-CoV-2 directed vaccins. Vorbeugung oder Linderung von Symptomen einer Covid-19 Erkrankung durch die Impfung mittels eines SARS-CoV-2 spezifischen Impfstoff., Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with Corona virus directed vaccins. Vorbeugung oder Linderung von Symptomen einer Covid-19 Erkrankung durch die Impfung mittels eines Corona Virus-spezifischen Impfstoff., Diseases [C] - Virus Diseases [C02]
 
 
NCT06441955: Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Recruiting
4
100
US
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Phramacotherapies, Physiological Evaluation, Immunologic Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Whole Genome Sequence, Multidisciplinary approach
Well- Konnect Healthcare Services and Research Firm, All of Us Research Program at the National Institute of Health
COVID-19, Long Haul
09/30
09/30
NCT06038617: Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

Recruiting
4
600
US
mRNA COVID-19 Vaccine, Pfizer COVID-19 Vaccine, Moderna COVID-19 Vaccine, Routine Childhood Vaccinations, Pneumococcal, DTaP, Haemophilus Influenzae Type B, MMR, Varicella, MMRV, Hepatitis A, Inactivated Poliovirus, Hepatitis B, Rotavirus, Influenza vaccines
Duke University, Kaiser Permanente, Columbia University, Children's Hospital Medical Center, Cincinnati, Centers for Disease Control and Prevention
Fever After Vaccination, Fever, Seizures Fever
07/25
12/25
NCT06585241: A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Adults to Prevent COVID-19

Active, not recruiting
4
100
US
mRNA-1273 Variant-containing Formulation
ModernaTX, Inc.
SARS-CoV-2
10/25
10/25
NCT06634797: A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Completed
4
1000
US
mRNA-1273.712, Placebo
ModernaTX, Inc.
Healthy Volunteers
01/25
01/25
NCT05212610: Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

Completed
4
103
US
Pfizer-BioNTech mRNA COVID-19 vaccine, Comirnaty
University of Michigan, The Wallace Foundation
COVID-19, Corona Virus Infection
03/25
03/25
COVIAAD, NCT04806113: COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

Completed
3
220
Canada
Moderna COVID-19 vaccine
McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval, Ministere de la Sante et des Services Sociaux
Covid19, Rheumatic Diseases, Rheumatoid Arthritis, SLE
06/21
06/22
REIN-TX, NCT05048940: Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.

Withdrawn
3
386
Europe
Janssen vaccine, Janssen Biologics B.V., EU/1/20/1525/001 EU/1/20/1525/002, Spikevax (Moderna) vaccine, MODERNA BIOTECH SPAIN, S.L., EU/1/20/1507/001
Instituto de Investigación Marqués de Valdecilla
Covid19
09/21
09/21
COVALL, NCT05028257: Allergy and COVID-19 Vaccines

Completed
3
117
Europe
COVID-19 Vaccines, Janssen COVID19 vaccine, Astra Zeneca COVID19 vaccine, Comirnaty Pfizer COVID19 vaccine, Moderna COVID19 vaccine
Assistance Publique - Hôpitaux de Paris
Anaphylactic Reaction, Vaccine Reaction
05/23
05/23
NCT05230953: Fourth COVID-19 Vaccine Dose- mRNA1273

Active, not recruiting
3
1000
RoW
mRNA1273 vaccine
Sheba Medical Center
COVID-19 Pandemic
07/24
07/24
MIACoV, NCT05228730: Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus ().

Terminated
3
13
RoW
Tozinameran - Standard dose, BNT162b2, Pfizer-BioNTech, Comirnaty, Tozinameran - fractional dose, Elasomeran - standard dose, mRNA-1273, Spikevax, Moderna, Elasomeran - fractional dose
Murdoch Childrens Research Institute, Coalition for Epidemic Preparedness Innovations, The Peter Doherty Institute for Infection and Immunity
COVID-19
07/22
11/22
SCTV01C-E-01-UAE-1, NCT05323461: A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

Active, not recruiting
3
1800
RoW
SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine, Comirnaty
Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
10/22
05/23
NCT05158140: Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Completed
3
850
US
V110, PNEUMOVAX™23, 23-Valent Pneumococcal Polysaccharide Vaccine, V114, VAXNEUVANCE™, 15-Valent Pneumococcal Conjugate, Vaccine, mRNA-1273, Placebo for V110, Placebo for V114
Merck Sharp & Dohme LLC
Pneumococcal Infection
02/23
02/23
NCT04860297: A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Completed
3
234
US
mRNA-1273
ModernaTX, Inc.
SARS-CoV-2
05/23
05/23
COVERALL, NCT04805125: Immunocompromised Swiss Cohorts Based Trial Platform

Completed
3
610
Europe
Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)
University Hospital, Basel, Switzerland, Swiss National Science Foundation, ModernaTX, Inc.
Immunocompromised Patients
09/23
09/23
V503-076, NCT05119855 / 2021-003591-13: Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine

Completed
3
165
US
9vHPV Vaccine, V503, GARDASIL®9, SILGARD®9, mRNA-1273 Vaccine, SARS-CoV-2 Vaccine, Moderna COVID-19 Vaccine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Papillomavirus Infections, Coronavirus Disease (COVID-19)
12/23
12/23
NCT05556720: Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Recruiting
3
960
RoW
Pfizer Bivalent COVID-19 Vaccine, Pfizer-BioNTech bivalent mRNA vaccine, COMIRNATY Original/Omicron BA.1, Moderna Bivalent mRNA vaccine, Moderna Bivalent Original/Omicron, Elasomeran/imelasomeran, Spikevax
Bayside Health, Monash University
HIV, Organ Transplantation, Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia, Multiple Myeloma, COVID-19 Vaccines
02/24
12/25
2023-000884-30: A Study of mRNA-1283 Compared with mRNA-1273 in Participants ≥12 Years of Age to Prevent COVID-19

Not yet recruiting
3
33574
Canada, Europe, US
mRNA-1283, mRNA-1273, Injection
ModernaTX, Inc., ModernaTX, Inc.
COVID-19, Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
RSVictory, NCT05330975: A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Completed
3
3317
US
Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
ModernaTX, Inc.
Respiratory Syncytial Virus
11/24
11/24
NCT06354998: A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

Completed
3
215
RoW
Investigational mRNA-1273.815, Licensed Spikevax Vaccine
ModernaTX, Inc.
SARS-CoV-2
05/24
05/24
2021-003591-13: Safety and Immunogenicity of 9vHPV Vaccine Coadministered With mRNA-1273 SARS-CoV-2 Vaccine

Not yet recruiting
3
160
US
Suspension for injection, Dispersion for injection, GARDASIL®9 (9vHPV vaccine), mRNA-1273 SARS-CoV-2 vaccine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Papilloma viral infection, Papilloma viral infection, Body processes [G] - Immune system processes [G12]
 
 
2024-000165-25: A Study to Evaluate the Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Not yet recruiting
3
1860
RoW, US
mRNA-1273.214, mRNA-1273.815, Injection
ModernaTX, Inc., ModernaTX, Inc.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT05436834 / 2024-000165-25: A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Recruiting
3
1860
US, RoW
mRNA-1273.214, mRNA-1273.815
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2
10/25
10/25
NextCOVE, NCT05815498 / 2023-000884-30: A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

Completed
3
14246
Europe, Canada, Japan, US
mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815
ModernaTX, Inc., ModernaTX, Inc.
COVID-19
04/25
04/25
NCT06694389: Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Recruiting
3
2450
Japan, RoW
mRNA-1083, Placebo, Licensed Influenza Vaccine, Influenza HA, Biken, and, Fluarix tetra, SARS-CoV-2 Vaccine, mRNA-1273
ModernaTX, Inc.
COVID-19, Influenza
12/25
12/25
NCT05387317: Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)

Withdrawn
3
800
RoW
Pfizer-BioNTech Standard dose, BNT162b2, Comirnaty, AstraZeneca Standard dose, ChAdOx1-S, Vaxzevria, Pfizer-BioNTech Fractional dose, AstraZeneca Fractional dose, Moderna Standard dose, mRNA-1273, Spikevax®, Moderna Fractional dose
Murdoch Childrens Research Institute, Universitas Padjadjaran, Health Development Policy Agency, Ministry of Health Republic of Indonesia, Coalition for Epidemic Preparedness Innovations, The Peter Doherty Institute for Infection and Immunity, Indonesia University
COVID-19
01/25
10/25
BOOST KIDNEY, NCT05022329: COVID-19 Vaccine Boosters in Patients With CKD

Terminated
2/3
273
Canada
Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 mRNA COVID-19 Vaccine, MODERNA SARS-CoV-2 Vaccine, mRNA-1273 SARS-CoV-2 Vaccine
Sunnybrook Health Sciences Centre, University Health Network, Toronto, Unity Health Toronto, Scarborough General Hospital, Providence Healthcare
Chronic Kidney Diseases, COVID-19
05/22
11/22
NCT05279365: PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

Recruiting
2/3
1000
US
Pfizer/BioNTech (BNT162b2), Moderna
DHR Health Institute for Research and Development
SARS CoV 2 Infection, COVID-19
08/22
08/23
NCT05249829 / 2022-000063-51: A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

Completed
2/3
3548
Europe
mRNA-1273.529, mRNA-1273, mRNA-1273.214
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2
06/23
06/23
CoVPN3008, NCT05168813: Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Completed
2/3
14232
RoW
Moderna mRNA-1273, Vaccine 3 Dose, Vaccine 2 Dose
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
SARS-CoV-2 Infection, HIV Infections, COVID-19
04/24
04/24
2023-000382-14: A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Not yet recruiting
2/3
4440
RoW, US
mRNA-1273, mRNA-1273.222, Injection, Spikevax
ModernaTX, Inc., ModernaTX, Inc., Biomedical Advanced Research and Development Authority
Coronavirus Disease 2019, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2022-000063-51: A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

Not yet recruiting
2/3
3924
Europe
mRNA-1273.529, mRNA-1273.214, mRNA-1273, Injection
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2, Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT04796896 / 2021-000281-15: A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Completed
2/3
11950
Canada, US
mRNA-1273, Placebo, mRNA-1273.214
ModernaTX, Inc., ModernaTX, Inc.
SARS-CoV-2
03/24
03/24
TeenCove, NCT04649151 / 2023-000382-14: A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Completed
2/3
4331
US, RoW
mRNA-1273, Placebo, mRNA-1273.222
ModernaTX, Inc., Biomedical Advanced Research and Development Authority
SARS-CoV-2
06/24
06/24
2021-002927-39: Preventive strategies against SARS-CoV-2 in kidney transplant recipients:Intervention A - vaccination: Study to test if vaccination with Ad26COVS1 or ChAdOx1-S results in a better immune response compared to a third dose of BNT162b2 or mRNA-1273 in kidney transplant recipients who did not develop an immune response following previous vaccination against COVID-19Intervention B - monoclonal SARS-CoV-2 antibody cocktail in kidney transplant recipients not responding to vaccination

Not yet recruiting
2
400
Europe
EVUSHELD, AZD7442, Suspension for injection, Concentrate for dispersion for injection, Dispersion for injection, Lyophilisate for solution for injection, COVID-19 Vaccine Janssen, Comirnaty, COVID-19 Vaccine Moderna, Vaxzevria
Medical University of Vienna, Medical University of Vienna
Intervention A - vaccinationPatients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccineSubstudy A: kidney transplant recipients who did not develop antibodies after a fourth doseIntervention B - monoclonal antibodiesKidney transpant recipients who do not develop neutralizing antibodies after at least two doses of SARS-CoV-2 vaccine, Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following vaccination, Diseases [C] - Immune System Diseases [C20]
 
 
CoviCompareM, NCT04748471: Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)

Not yet recruiting
2
180
NA
mRNA-1273
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Prevention of COVID19
07/21
01/23
NCT05027672: Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.

Active, not recruiting
2
348
RoW
Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5), Gam-COVID-Vac (rAd26) / ChAdOx1 nCoV-19, Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd26), Gam-COVID-Vac (rAd26) / mARN-1273
Ministerio de Salud de Ciudad Autónoma de Buenos Aires
COVID-19 Vaccines
08/21
09/21
2021-002356-37: Study about the response to the administration of a third dose of mRNA-1273 vaccine (COVID19 vaccine Moderna) in renal transplants with immunological failure initial to vaccination ESTUDIO SOBRE LA RESPUESTA A LA ADMINISTRACIÓN DE UNA TERCERA DOSIS DE LA VACUNA mRNA-1273 (COVID19 Vaccine Moderna) EN TRASPLANTADOS RENALES CON FRACASO INMUNOLÓGICO INICIAL A LA VACUNACION

Ongoing
2
80
Europe
COVID-19 Vaccine Moderna dispersion for injection
Fundació Clinic per a la Recerca Biomèdica (FCRB), Fundació Clinic per a la Recerca Biomèdica (FCRB)
COVID19 vaccine in kidney transplant patients Vacuna COVID19 en pacientes trasplantados renales, COVID19 vaccine in kidney transplant patients Vacuna COVID19 en pacientes trasplantados renales, Diseases [C] - Virus Diseases [C02]
 
 
ECEHeVac, NCT04988048: Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina

Recruiting
2
1760
RoW
COVID-19 vaccines, SPUTNIK-V (Gam-COVID-Vac), SINOPHARM (BBIBP-CorV), AstraZeneca (ChAdOx1 nCoV-19 vaccine AZD1222), Moderna (mRNA-1273 or Spikevax)
Ministry of Public Health, Argentina, Russian Direct Investment Fund
COVID-19 VACCINE, Covid19
09/21
02/22
2021-004526-29: A multinational, phase 2, randomised, adaptive protocol to assess immune response and side effects of different COVID-19 vaccines given in older adults (75 years and older) already vaccinated against SARS-CoV-2

Ongoing
2
600
Europe
Spikevax, Concentrate for dispersion for injection, Dispersion for injection, Comirnaty, Spikevax
University of Cologne, European Commission
Prevention of COVID-19 infection, Prevention of COVID-19 infection, Body processes [G] - Immune system processes [G12]
 
 
 

Download Options